Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell ImmunotherapiesLaurent Poirot, Julianne Smith, Brian Philip et al.|Cancer Research|2015Cited by 600
In vitro Inactivation of Latent HSV by Targeted Mutagenesis Using an HSV-specific Homing EndonucleaseMartine Aubert, Keith R. Jerome, Andrew M. Scharenberg et al.|Molecular Therapy — Nucleic Acids|2014Cited by 50
Characterization of three loci for homologous gene targeting and transgene expressionJustin Eyquem, Julianne Smith, Laurent Poirot et al.|Biotechnology and Bioengineering|2013Cited by 25
<i>Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia</i>Gail J. Roboz, Naveen Pemmaraju, Daniel J. DeAngelo et al.|Blood|2020Cited by 11
Pre-TCRα supports CD3-dependent reactivation and expansion of TCRα-deficient primary human T-cellsRomán Galetto, Andrew M. Scharenberg, Céline Lebuhotel et al.|Molecular Therapy — Methods & Clinical Development|2014Cited by 10